Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use

AIDS Research and Human Retroviruses

Volumn 27, Issue 7, 2011, Pages 719-725

  Connoy, Abbie ^a   Turner, Jolyn ^a   Núñez, Marina ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKERATIN 18; GELATINASE A; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; DRUG USE; FEMALE; GENE OVEREXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 79959848835     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0224     Document Type: Article

References (20)

1. Sulkowski MS and Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 2003;138:197-207. (Pubitemid 36231625)
2. Di Martino V, Rufat P, Boyer N, et al.: The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001;34(6):1193-1199. (Pubitemid 33096592)
3. Allory Y, Charlotte F, Benhamou Y, Opolon P, Le Char-pentier Y, and Poynard T: Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study. The MULTIVIRC group. Hum Pathol 2000;31(1):69-74. (Pubitemid 30054390)
4. Bonacini M and Puoti M: Hepatitis C in patients with human immunodeficiency virus infection: Diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch intern Med 2000;160(22):3365-3373.
5. Calabrese F, Pontisso P, Pettenazzo E, et al.: Liver cell apo-ptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepa-tology 2000;31:1153-1159. (Pubitemid 30233241)
6. Bantel H, Lügering A, Poremba C, et al.: Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001;34: 758-767. (Pubitemid 32928001)
7. Bantel H, Lügering A, Heidemann J, et al.: Detection of caspase activation in the sera from patients with chronic HCV infection is associated with fibrotic liver injury. He-patology 2004;40:1078-1087. (Pubitemid 39425563)
8. Boeker KH, Pehle B, Steinmetz C, et al.: Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepatogas-troenterology 2000;47:812-819. (Pubitemid 30417300)
9. Lichtinghagen R, Michels D, Haberkorn CI, et al.: Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibro-proliferative process in the liver during chronic hepatitis C. J Hepatol 2001;34:239-247. (Pubitemid 32176445)
10. Leroy V, Monier F, Bottari S, et al.: Circulating matrix metalloproteinases 1, 2, 9 and their inhibitor TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: Comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004;99:271-279. (Pubitemid 38279869)
11. Rosenberg WM, Voelker M, Thiel R, et al., and the European Liver Fibrosis Group: Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127: 1704-1713. (Pubitemid 39575849)
12. Kasahara A, Hayashi N, Mochizuki K, et al.: Circulating matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997;26:574-583. (Pubitemid 27112723)
13. Mastroianni CM and Liuzzi GM: Matrix metalloproteinase dysregulation in HIV infection: Implications for therapeutic strategies. Trends Mol Med 2007;13:449-459. (Pubitemid 350086978)
14. Larrousse M, Laguno M, Segarra M, et al.: Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir immune Defic Syndr 2007;46:304-311. (Pubitemid 350287357)
15. Mastroianni CM, Liuzzi GM, D'Ettorre G, et al.: Matrix metalloproteinase-9 and tissue inhibitors of matrix metallo-proteinase-1 in plasma of patients co-infected with HCV and HIV. HIV Clin Trials 2002;3:310-315. (Pubitemid 34830682)
16. Anatol P, Robert F, and Danuta P: Effect of interferon al-pha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C. World J Gastroenterol 2005;11:1854-1858. (Pubitemid 40520784)
17. Brau N, Salvatore M, Rios-Bedoya CF, et al.: Slower fibrosis progression in HIV/HCV coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55. (Pubitemid 41772515)
18. Pineda JA, Garćia-García JA, Aguilar-Guisado M, et al.: Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46:622-630. (Pubitemid 47436106)
19. Qurishi N, Kreuzberg C, Lüchters G, et al.: Effect of antiretroviral therapy on liver related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-1713. (Pubitemid 37468321)
20. Thein HH, Yi Q, Dore G, and Krahn M: Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008;22:1979-1991.